No Data
DNA, ETC [Stocks with Interest Viewed from Changes in Volume]
Closing price compared to the previous day Volume *<1483> iShares 2,896,811,217 *<162A> AI Select Daily Stock ETN 1,032,520,051,26 *<7044> Piarra 250,192,639,100 *<1474> One ETF Nikkei 26,190,695,954,7 *<2323> fonfun 884,118,107,200 *<1369> DIAM 225,405,108,501,5507 *<1625> Electronics Precision 391,106,701,466 *<234A>
Stocks that moved the day before part 2: E-store, Kyogoku Transportation, fonfun, ETC.
Stock Name <Code> Closing Price on the 27th ⇒ Change from Previous Day FIG <4392> 286 -121 Selling pressure due to the dividend ex-rights in December. Mitsubishi Automobiles <7211> 550.1 -12.8 The decline in Nissan's stock price, considering the consolidation ratio, also weighs heavily. Oenon HD <2533> 399 -81 Selling pressure due to December dividend ex-rights, etc. AD Works Group <2982> 210 -4 The impact of ex-rights as a high-yield stock. Kusuri no Aoki <3549> 3215 -369-11 Month operating.
Emerging Markets stock digest: Piara briefly hits the upper limit, and BASE surges.
＜4447＞ PB Systems 597 +7 rebound. It was announced that a 360° theater projection system for Akagane Museum in Niihama City, Ehime Prefecture was ordered from Heart Network, receiving positive feedback. The company's new version of MetaWalkers Advanced is designed to meet the renewal demand for theaters held by municipalities and companies nationwide, allowing flexible selection of screen shapes and number of projection devices for existing theater facilities.
Stocks reaching the upper and lower limits in the first half of the trading session.
■ Limit Up <2928> RIZAP Group <297A> Alpico Holdings <298A> GVA TECH <304A> Forvia <7044> Piala <7067> Branding Technology ■ Limit Down * Includes temporary limit up/down (indicative price).
Hot Stocks Digest (Morning Session): DeNA, Kyowa Kirin, Piara, ETC.
Research Pharmaceuticals <4521>: 4,497 yen (+323 yen) significantly continues to rise. Announced the signing of an exclusive license agreement to grant J&J rights related to the development, manufacturing, and commercialization of the 'STAT6 Program.' This program is under development as a next-generation oral treatment for type 2 inflammatory diseases (such as atopic dermatitis and asthma). It is expected to receive a one-time contract payment of 30 million dollars during the fiscal year ending in March 2025, as well as up to 1.2 billion and 17.5 million dollars in milestone revenues, with a single-digit percentage of revenue.
December 27 [Today's Investment Strategy]
[Selected Stocks by Fisco] 【Material Stocks】 Kaken Pharmaceutical <4521> 4174 yen (12/26) Main products include the nail fungus treatment 'Klenafin' and the joint function improvement drug 'Alts'. The company announced the signing of a contract granting Johnson & Johnson exclusive rights for the development, manufacturing, and commercialization globally of the 'STAT6 Program', which is being developed as a next-generation oral treatment for type 2 inflammatory diseases (such as atopic dermatitis and asthma).
No Data